Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder

This study has been completed.
Sponsor:
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00036101
First received: May 7, 2002
Last updated: November 7, 2013
Last verified: September 2007
  Purpose

The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder.


Condition Intervention Phase
Bipolar Disorder
Drug: aripiprazole
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Study Start Date: February 2002
Study Completion Date: January 2003
Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients with acute symptoms of Bipolar Disorder

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00036101

  Hide Study Locations
Locations
United States, Alabama
Local Institution
Tuscaloosa, Alabama, United States
United States, Arizona
Local Institution
Little Rock, Arizona, United States
United States, California
Local Institution
Beachwood, California, United States
Local Institution
Chula Vista, California, United States
Local Institution
Riverside, California, United States
Local Institution
San Clemente, California, United States
Local Institution
San Diego, California, United States
Local Institution
Stanford, California, United States
United States, District of Columbia
Local Institution
Washington, District of Columbia, United States
United States, Florida
Local Institution
North Miami, Florida, United States
Local Institution
Winter Park, Florida, United States
United States, Hawaii
Local Institution
Honolulu, Hawaii, United States
United States, Illinois
Local Institution
Chicago, Illinois, United States
United States, Indiana
Local Institution
Indianapolis, Indiana, United States
United States, Kentucky
Local Institution
Louisville, Kentucky, United States
United States, Massachusetts
Local Institution
Belmont, Massachusetts, United States
Local Institution
Newton Center, Massachusetts, United States
United States, Michigan
Local Institution
New Baltimore, Michigan, United States
United States, New York
Local Institution
Lawrence, New York, United States
United States, North Carolina
Local Institution
Butner, North Carolina, United States
United States, Ohio
Local Institution
Cincinnati, Ohio, United States
Local Institution
Medina, Ohio, United States
United States, Pennsylvania
Local Institution
Philadelphia, Pennsylvania, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
Houston, Texas, United States
United States, Virginia
Local Institution
Falls Church, Virginia, United States
United States, Washington
Local Institution
Bellevue, Washington, United States
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00036101     History of Changes
Other Study ID Numbers: CN138-074
Study First Received: May 7, 2002
Last Updated: November 7, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Bipolar I Disorder

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Aripiprazole
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on April 17, 2014